Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old

Multicenter, Open, Prospective, Randomized Trial of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old

Reaching active aging makes it important to implement new methods affecting the biological age of a person. Biochemical parameters of a blood test are aging biomarkers that are ones of the most accessible for testing. We know that, with age, there is increase in levels of LDL, triglycerides, homocysteine and other biomarkers relating the body state.

Methods of extracorporeal hemocorrection showed good results in this area. For instance, the use of plasmapheresis is very effective during prophylaxis, treatment and rehabilitation after various diseases/injuries. The main effects of plasmapheresis are related to removal of endo- and exotoxins, including products of lipid peroxidation, and to draining effect as a result of a heavy flow of interstitial fluid containing products of pathometabolism into the blood stream within concentration gradient (by "dynamic equilibrium" in concentration of different substances in intracellular, interstitial and intravascular compartments). These effects are also related to release of receptors, their sensitization to their own neurohumoral regulation mechanisms, to insulin, in particular (as consequences, lower glucose tolerance, lower substrate glycation).

Study Overview

• Status: Recruiting
• Conditions: Cardiovascular Diseases; Nervous System Diseases; Urologic Diseases; Diabetes; Neuromuscular Diseases; Hypercholesterolemia; Gout; Hyperbilirubinemia; Hyper IgE Syndrome; Hyper-LDL-cholesterolemia; Hyper Beta Lipoproteinemia; Hyper Eosinophilic Syndrome
• Intervention / Treatment: Procedure: plasma exchange with albumin; Procedure: plasma exchange without albumin

Detailed Description

Reaching active aging makes it important to implement new methods affecting the biological age of a person. Biochemical parameters of a blood test are aging biomarkers that are ones of the most accessible for testing. We know that, with age, there is increase in levels of LDL, triglycerides, homocysteine and other biomarkers relating the body state.

One of the initial approaches of anti-ageing therapy is detoxification, reocorrection and immunocorrection. Methods of extracorporeal hemocorrection showed good results in this area. For instance, the use of plasmapheresis is very effective during prophylaxis, treatment and rehabilitation after various diseases/injuries. The main effects of plasmapheresis are related to removal of endo- and exotoxins, including products of lipid peroxidation, and to draining effect as a result of a heavy flow of interstitial fluid containing products of pathometabolism into the blood stream within concentration gradient (by "dynamic equilibrium" in concentration of different substances in intracellular, interstitial and intravascular compartments). These effects are also related to release of receptors, their sensitization to their own neurohumoral regulation mechanisms, to insulin, in particular (as consequences, lower glucose tolerance, lower substrate glycation).

Thus, at this stage, experts assess effectiveness and organize data of existing prevention methods for premature aging and correction of aging biomarkers, as well as develop comprehensive programs for drug-free and pharmacological intervention. Introduction of the body detoxification method based on extracorporeal hemocorrection (developed in FGBU Russian Scientific Center for Medical Rehabilitation and Balneology of Ministry of Health of Russian Federation) may extend the range of effective and safe methods within such programs, as well as lower patients' biological age and, thus, lower risks of developing age-related diseases, decrease number of disability cases, which can contribute to life prolonging and improvement of its quality.

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ilmira Gilmutdinova; Phone Number: +79686861979; Email: gilm.ilmira@mail.ru

Study Locations

• Russian Federation
  • Moscow, Russian Federation, 121099
    • Recruiting
    • Federal State Budgetary Institution "National Medical Center for Rehabilitation and Balneology" of the Ministry of Health of Russia
    • Contact: Ilmira Gilmutdinova; Phone Number: 89686861979; Email: gilm.ilmira@mail.ru
  • Orenburg, Russian Federation, 460018
    • Recruiting
    • Orenburg regional clinical blood transfusion station
    • Contact: Rinat Gilmutdinov; Phone Number: +79033608175; Email: orenrma@mail.ru

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed informed consent form.
• Men and women aged 40-55.
• Body mass index <30 kg / m2.
• Level increase of one or several aging markers.
• Understanding of requirements for study participants, written consent to participate in the study (including volunteer's consent for his/her health information related to the study to be used and passed on) and to perform procedures outlined in study protocol.
• Negative pregnancy test for women of childbearing potential.

Non-inclusion Criteria:

• Refusal to participate in the study.
• Any health conditions that, according to investigators, might prevent volunteers from participating in the study.
• Mental disorders, past medical history included.
• 10 + alcohol units per week (one alcohol unit equals 0,5 l of beer, 200 ml of wine or 50 ml of hard liquors) or any records of alcohol addiction.
• Drug addiction, chemical abuse.
• Pregnancy or breastfeeding.
• Past medical history of severe allergic reactions.
• General contraindications to plasmapheresis procedures.
• Any other health conditions or reasons that, according to investigators, might increase risks for participants or reduce the likelihood of results needed to meet the study goals.

Exclusion Criteria:

• Voluntary refusal to participate in the study.
• Investigator doctor's decision on participant's exclusion for this participant's own benefit.
• Participant refuses to cooperate with investigator or is undisciplined.
• In case participant misses one or several study procedures or follow-up visits.
• Development of severe adverse reactions or severe diseases/conditions unrelated to the study, requiring withdrawal from therapy.
• Positive pregnancy test.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: plasmapheresis with albumin compensation; a course of hardware plasmapheresis procedures with replacement by colloidal (5% albumin solution) and crystalloid solutions (saline) in a ratio of 1: 3	Procedure: plasma exchange with albumin; plasma exchange with albumin, two per week, 110% of the circulating plasma volume; Other Names: plasmapheresis with albumin
Experimental: plasmapheresis without albumin compensation; a course of hardware plasmapheresis procedures without replacement by albumin solution, only crystalloid solutions (saline).	Procedure: plasma exchange without albumin; plasma exchange without albumin, two per week, 110% of the circulating plasma volume; Other Names: plasmapheresis without albumin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count	Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count at visit 6, compared with initial values (visit 0).	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count	Dynamics summary for aging biomarkers' values assessed by a patient's biochemical blood count at visit 5, compared with initial values (visit 0).	17 (+/- 2) days
Dynamics summary for aging biomarkers' values assessed by a patient's complete blood count	Dynamics summary for aging biomarkers' values assessed by a patient's complete blood count at visits 5 and 6, compared with initial values (visit 0).	1 month
Dynamics summary for aging biomarkers' values assessed by a patient's blood serological test	Dynamics summary for aging biomarkers' values assessed by a patient's blood serological test at visits 5 and 6, compared with initial values (visit 0).	1 month
Dynamics summary for aging biomarkers' values assessed by a patient's coagulation test	Dynamics summary for aging biomarkers' values assessed by a patient's coagulation test at visits 5 and 6, compared with initial values (visit 0).	1 month
Dynamics of results according to the method of "phenotypic age"	Dynamics of results according to the method of "phenotypic age" assessment with the use of values of complete and biochemical blood counts at visits 5 and 6, compared with initial values (visit 0). An assessment of the "phenotypic age" will be carried out (Morgan E. et al., 2018). For counting, 10 markers are used: albumin, creatinine, glucose, C-reactive protein, percentage of lymphocytes, average cell volume, distribution width of erythrocytes, alkaline phosphatase, leukocyte count, chronological age.	1 month
Dynamics of results according to the method of biological age	Dynamics of results according to the method of biological age assessment with the use of values of complete and biochemical blood counts at visits 5 and 6, compared with initial values (visit 0). The biological age will be assessed by the method of Putin E., Mamoshina P. et al., 2016. The following markers are used for calculation by this method: albumin, glucose, urea, cholesterol, total protein, sodium, creatinine, hemoglobin, total bilirubin, triglycerides , HDL cholesterol, LDL cholesterol (Friedewald), calcium, potassium, hematocrit, MCHC, MCV, platelets, erythrocytes (erythrocytes), weight, height. An online system available at http://www.aging.ai will be used to estimate biological age.	1 month
Dynamic pattern according to ECG results	Dynamic pattern according to ECG results in 12 leads at visits 5 and 6, compared with initial values (visit 0).	1 month
Dynamic pattern according to results of vascular ultrasonography	Dynamic pattern according to results of vascular ultrasonography at visits 5 and 6, compared with initial values (visit 0).	1 month
SF-36 scale	Change of scores according to every scale out of all 8 scales from the SF-36 questionnaire at visits 5, 6 and 7, compared with initial values (visit 0).	1 month
HAM questionnaire	Dynamics of subjective assessment of a patient's current psycho emotional state (HAM questionnaire) at visits 5, 6 and 7, compared with initial values (visit 0). The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), abbreviated HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.	1 month
scales of the "Health-Promoting Lifestyle Profile"	Change of scores according to every scale out of 6 scales of the "Health-Promoting Lifestyle Profile" questionnaire at visits 5, 6 and 7, compared with initial values (visit 0).	1 month

Collaborators and Investigators

• Sponsor: National Medical Research Center for Rehabilitation and Balneology
• Collaborators: Pirogov Russian National Research Medical University; DNKOM LLC; The Orenburg Regional Clinical Hospital
• Investigators: Study Chair: Ilmira Gilmutdinova, Federal State Budgetary Institution "National Medical Center for Rehabilitation and Balneology" of the Ministry of Health of Russia

Study record dates

Study Major Dates

• Study Start (Anticipated): May 12, 2021
• Primary Completion (Anticipated): October 30, 2022
• Study Completion (Anticipated): December 30, 2022

Study Registration Dates

• First Submitted: May 18, 2021
• First Submitted That Met QC Criteria: May 18, 2021
• First Posted (Actual): May 21, 2021

Study Record Updates

• Last Update Posted (Actual): May 21, 2021
• Last Update Submitted That Met QC Criteria: May 18, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: albumin; plasmapheresis; plasma exchange; biomarkers of aging; age-related diseases
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Disease; Hematologic Diseases; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Lipid Metabolism Disorders; Leukocyte Disorders; Hyperlipidemias; Dyslipidemias; Eosinophilia; Lipid Metabolism, Inborn Errors; Phagocyte Bactericidal Dysfunction; Hyperlipoproteinemias; Primary Immunodeficiency Diseases; Cardiovascular Diseases; Syndrome; Nervous System Diseases; Hypercholesterolemia; Hypereosinophilic Syndrome; Hyperlipoproteinemia Type II; Urologic Diseases; Hyperbilirubinemia; Neuromuscular Diseases; Job Syndrome
• Other Study ID Numbers: RU-RB-01-01-21 of 08.02.2021

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes